Premium
Sarcomas of the sinonasal tract
Author(s) -
Kauke Martin,
Safi AliFarid,
Grandoch Andrea,
Nickenig HansJoachim,
Zöller Joachim,
Kreppel Matthias
Publication year - 2018
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.25108
Subject(s) - medicine , overall survival , retrospective cohort study , sarcoma , cohort , neoplasm , multimodal therapy , disease , oncology , surgery , pathology
Background Sinonasal sarcomas are rare and heterogeneous in nature. Continuously collecting data influencing the prognosis is fundamental for optimizing therapeutic assessment of this highly destructive neoplasm. Methods We conducted a single‐institution retrospective cohort study considering 27 patients with sinonasal sarcoma. Results The overall survival (OS) rates for 1 year and 5 years were calculated as 74% and 36%, respectively. Extent of the primary tumor ( P = .010), nodal spread ( P = .009), and age ( P = .004) significantly reduced the OS. Disease‐free survival (DFS) was significantly reduced by age ( P = .003), extent of the primary ( P = .006), nodal ( P = .004), and hematogenous ( P = .048) spread. Multimodal therapy including surgery improved the OS and DFS rates ( P < .05). Conclusion Prognosis is poor due to late disease recognition. However, multimodal therapeutic regimens, including surgery, may improve the outcome.